Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US Update 8/3/2022
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
View this post in the Community →
Similar Community Posts Join
5 / 444 resultscommunity KX-826+Minoxidil Outperforms Minoxidil Alone for AGA Treatment: 30+ New Hairs/cm² (24 Weeks, P=0.0075)
KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.
community KX-826 1% Phase II Results from China Just Dropped
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community KX-826: Long-Term Safety Results are out!
KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
Related Research
6 / 219 results
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
New treatments for hair loss show promise but need more testing for effectiveness and safety.
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.
research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.